Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD, Ghezelayagh TS, Lian S, Zhang Y, Fredrickson J, Nachmanson D, Baker KT, Radke MR, Hun E, Norquist BM, Emond MJ, Swisher EM, Risques RA. Krimmel-Morrison JD, et al. Among authors: ghezelayagh ts. Gynecol Oncol. 2020 Feb;156(2):407-414. doi: 10.1016/j.ygyno.2019.11.124. Epub 2019 Dec 12. Gynecol Oncol. 2020. PMID: 31839337 Free PMC article.
Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M. Bartlett TE, et al. Among authors: ghezelayagh ts. Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5. Genome Med. 2022. PMID: 35701800 Free PMC article. Clinical Trial.
Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M. Bartlett TE, et al. Among authors: ghezelayagh ts. Genome Med. 2022 Jul 19;14(1):76. doi: 10.1186/s13073-022-01086-y. Genome Med. 2022. PMID: 35854342 Free PMC article. No abstract available.
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS, Kohrn BF, Fredrickson J, Manhardt E, Radke MR, Katz R, Gray HJ, Urban RR, Pennington KP, Liao JB, Doll KM, Simons EJ, Burzawa JK, Goff BA, Speiser P, Swisher EM, Norquist BM, Risques RA. Ghezelayagh TS, et al. Cancer Res Commun. 2022 Oct;2(10):1282-1292. doi: 10.1158/2767-9764.crc-22-0314. Epub 2022 Oct 27. Cancer Res Commun. 2022. PMID: 36311816 Free PMC article.
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.
Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, Gray HJ, Goff BA, Shah CA, Neubauer NL, Dai JY, Tanyi JL, Liao JB. Ghezelayagh TS, et al. Eur J Gynaecol Oncol. 2023 Feb;44(1):17-25. doi: 10.22514/ejgo.2023.002. Epub 2023 Feb 14. Eur J Gynaecol Oncol. 2023. PMID: 36874058 Free PMC article.